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Abstract  
Objective: The aim of this paper is to provide detailed guidance on how to incorporate 
health equity within the GRADE (Grading Recommendations Assessment and Development 
Evidence) evidence to decision process. 
Study design and setting: We developed this guidance based on the GRADE evidence to 
decision (EtD) framework, iteratively reviewing and modifying draft documents, in person 
discussion of project group members and input from other GRADE members.  
Results: Considering the impact on health equity may be required, both in general 
guidelines, and guidelines that focus on disadvantaged populations. We suggest two 
approaches to incorporate equity considerations: 1) assessing the potential impact of 
interventions on equity and; 2) incorporating equity considerations when judging or weighing 
each of the evidence to decision criteria. We provide guidance and include illustrative 
examples.  
Conclusion: Guideline panels should consider the impact of recommendations on health 
equity with attention to remote and underserviced settings and disadvantaged populations. 
Guideline panels may wish to incorporate equity judgments across the evidence to decision 
framework. 
This is the fourth and final paper in a series about considering equity in the GRADE 
guideline development process. This series is coming from the GRADE equity subgroup.  
Keywords: Health equity, disadvantaged, underserved, special populations, evidence to 
decision process, GRADE guidelines  
 
Running title: GRADE Equity: How to consider health equity within the evidence to decision 
process 
Key Points 
• Panels should consider the potential for an intervention to have unwanted effects on 
equity when moving from evidence to decision making.  
• Incorporating health equity judgments into other evidence to decision criteria should 
be considered, both in general guidelines and in disadvantaged population specific 
guidelines. 
• Panels may wish to point out these potential adverse effects such that decision 
makers could take mitigating actions in their implementation and monitoring of the 
recommendation. 
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Background 
Health care recommendations may alleviate or worsen health inequities [1–3] . For example, 
recommendations for testing and treatment for hepatitis C may worsen the health of 
disadvantaged populations with hepatitis C, relative to less disadvantaged populations, if 
recommendations do not consider how to ensure medical care and treatment for all hepatitis 
C positive populations [4].  
In this series, health inequity is defined as avoidable differences in health that are 
considered unfair or unjust [5]. We refer to disadvantaged populations as those that are at 
risk for health inequities and we use the acronym PROGRESS-Plus1 to refer to the factors 
associated with social disadvantage [6]. 
Recognizing the importance of health equity in guidelines, the GRADE working group 
established an Equity working group in 2013.  This paper  is the last in a four-part series of 
papers considering health equity in guideline development [7–9].  This paper focuses on how 
to consider and address health equity in the GRADE evidence to decision (EtD) process. 
The GRADE EtD frameworks support explicit judgments about the main factors that 
influence the strength of recommendations, including impact on health equity [2,3]. These 
criteria include the priority of the problem, how substantial desirable and undesirable health 
effects are, certainty of the evidence of effects, how people value the main outcomes, 
whether desirable effects outweigh undesirable health effects, resource requirements and 
whether the net health benefits are worth the incremental cost, impact on equity, 
acceptability to stakeholders, and feasibility of the intervention [2,3]. The EtD framework can 
be used for different types of decisions, including clinical recommendations, tests, coverage 
decisions, and health system and public health recommendations [2,3]. There is a debate 
within the guideline community about the relevance of health equity for individual decisions, 
which we describe in paper 1 of this series [7]. GRADE guidance states that from a 
population perspective, equity, acceptability, and feasibility are important considerations, 
however the importance of these criteria is often limited from an individual patient 
perspective [2], but this needs further discussion. 
 
EtD frameworks allow guideline panel to assess criteria and, if appropriate, make subgroup 
recommendations for specific settings and disadvantaged populations. In addition to the 
specific EtD criteria of “equity impact”, it may be desirable to assess health equity across 
other criteria in the EtD.  For example, the Canadian Migrant Health Guideline Panel in 
considering [10] evidence for HIV testing in populations coming from HIV endemic countries, 
the panel sought evidence on acceptability (one of the EtD criteria) for refugee populations, 
and this led to the recommendation for inclusion of voluntary and anonymous testing options 
to improve access to testing. Therefore, by assessing health equity considerations within 
other EtD criteria, guideline panels may improve the comprehensiveness of judgments.  
This paper argues that, in addition to assessing equity impact as a specific criterion, it may 
be useful to systematically consider health equity issues within each of the GRADE EtD 
criteria. The examples within this paper launch a discussion as to the best way to integrate 
equity considerations within the EtD process. We will show how assessing equity across the 
criteria can influence the strength of the recommendation.  
 
                                               
1PROGRESS stands for: Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, 
Education, Socioeconomic status, or Social capital [2]. The “Plus” in “PROGRESS-Plus” indicates that other 
characteristics, such as age, disability, sexual orientation, time-dependent situations and relationships, may also 
be at the heart of health inequities as they pertain to disadvantaged populations.  
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Existing guidance 
Over the past 10 years, authors have proposed questions to incorporate equity during the 
development of guidelines [1,11] . The WHO guideline manual includes guidance for panels 
addressing equity, gender and human rights [5,12]. The previous papers in the series 
address how to consider equity in formulating the research question [8] and rating the 
certainty of synthesized evidence [9]. Finally, the EtD framework publications provide the 
guidance that this paper builds upon [2,3,13]. 
 
Guidance on rating health equity in evidence to decision criteria 
The GRADE EtD process includes three steps: 1) formulating the question; 2) making an 
assessment for each of the relevant criteria that determine a decision; and 3) drawing 
conclusions. 
1. Formulating the Question   
The GRADE EtD process begins with the formulation of review questions, with details about 
the PICO (population, interventions, comparisons and outcome) and other details relevant to 
the perspective and background. In the second paper of this series, Akl et al. outlines how 
health equity can be considered within panel formulation and development of equity-
sensitive questions [8]. Analysis focusing on resource limited settings, specific populations 
(e.g. disadvantaged) can lead to different recommendations [2]. For example, an equity 
sensitive question  focused on implementation issues in populations at high risk for hepatitis 
C (Box 1 shows that the high prevalence subgroups were identified at the question 
formulation stage)  [14].  The question may highlight health equity in different ways, such as 
by focusing on a disadvantaged population or by assessing effects across subgroups that 
may be disadvantaged. 
 
Box 1: Evidence to Decision (EtD) framework, question section 
Question: Should the general population in Canada be screened for HCV? 
Population: Canadian general population  
Intervention: screen, link to care, and treat as indicated 
Comparison: do not screen 
Main outcomes: morbidity and mortality 
Setting: Canada, a high income country with overall low HCV prevalence 
Perspective: population perspective (health system)  
Subgroups: High HCV prevalence (e.g. certain migrant populations, and IV drug 
users) 
Background New treatments emerging but not trials on screening and on patient 
important outcomes, and considerable concern for resource requirements  
Adapted from Canadian Task Force on Preventive Health Care Screening for HCV [14] 
  
2. Making an assessment of each relevant criterion      
We provide guidance and relevant examples and assess and address health equity for each 
criterion of the EtD framework.  
 
Is the problem a priority? 
Are the consequences of the problem serious, that is, severe or important in terms of the 
potential benefits or savings [2]. The more severe the consequences of the problem (for 
example, the more debilitating, life threatening or expensive), the more likely a strong 
recommendation may be made.  Many diseases disproportionately affect low income 
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populations (e.g. cardiovascular disease, infectious disease, motor vehicle accidents) [15]. In 
addition, disadvantaged populations may face limited access to appropriate treatment and 
care (e.g. cataracts in low income countries or tuberculosis in indigenous populations). In 
these cases, guideline panels might consider these conditions as high priority because they 
place value on redressing unfair burden carried by disadvantaged populations. Similarly, 
undernutrition and its correlation to poor educational consequences in low income 
neighborhoods, may mean school feeding programs may reduce health inequities and will 
be seen as a priority [16].   
 
How substantial are the undesirable and desirable anticipated health effects? 
With larger desirable health effects, it is more likely that the intervention should be 
recommended, whereas larger undesirable effects (including burden and inconvenience) 
may lead to not recommending an intervention. Assessing both desirable and undesirable 
effects for specific disadvantaged populations may lead to different recommendations. When 
assessing the size and importance of effects, it is important to consider both relative and 
absolute effects.  Even though relative effects are similar across populations, absolute 
effects may differ if baseline risks are substantially different for disadvantaged populations 
[17].  
 
What is the overall certainty of the evidence of effects? 
The less certain the evidence is for the main desirable and undesirable effects, the less likely 
it is that a strong recommendation should be made for a population [3]. If the intervention is 
recommended and implemented, it is more likely that the intervention should be evaluated. 
GRADE recommends rating imprecision, indirectness and other certainty of evidence 
domains as part of an iterative process that is akin to, but not equal to, statistical accuracy 
[18].  
Indirectness is an important criterion when considering disadvantaged populations, as 
described in a previous paper of this series [9]. For example, the available evidence may be 
limited for disadvantaged populations as these groups are often under-represented in clinical 
and population research.  If there is strong rationale to expect the relative treatment effect to 
substantially vary between the general population and one or more disadvantaged groups, 
the panel could rate down the certainty of effect for indirectness. However, as described in 
the second paper of this series [8] this scenario is extremely rare.  Panels should be 
cautious in rating down certainty of effects for indirectness unless there is a strong rationale, 
such as evidence of subgroup effects or effect modifiers, for why the evidence would not 
apply to the specific disadvantaged group. Similarly, it is possible (but generally less likely) 
that a greater body of evidence may exist for a disadvantaged population (e.g. as a 
consequence of more research having been conducted in response to a high burden in this 
population). Under such a situation, it is possible that greater certainty in the evidence may 
result in a different recommendation that is targeted at disadvantaged groups. However, 
potential for stigma or other adverse consequences that may arise from targeted 
recommendations should be considered [19].   
 
Is there important uncertainty about or variability in how much people value the main 
outcomes? 
How people value important outcomes and the variability in how they value them (the extent 
that individuals with different views would make different decisions), can impact the strength 
of recommendations. Greater uncertainty about these values will decrease the likelihood of a 
strong recommendation [2]. Valuation of outcomes also depends on when the outcomes 
occur and on the values about future outcomes compared to short-term outcomes. Certain 
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disadvantaged populations may value the main outcomes differently than the general 
population. Explicitly considering the views of disadvantaged groups [20] concerning the 
importance of outcomes helps panels to decide whether adapting recommendations for 
subgroups is warranted. For example, refugee populations from tuberculosis (TB) endemic 
countries show less concern for latent (asymptomatic) TB than the general population [21]. 
The limited concern for latent TB of certain patients should be factored into 
recommendations for the implementation of Mantoux testing. Evidence measuring views of 
outcomes in a range of populations, however, may be limited.  
As another example, in the development of the Australian renal guidelines, discrete choice 
analyses identified that taking indigenous people living in rural communities valued the 
additional time at home over improved survival, and this led to a conditional recommendation 
to offer a delay in instituting renal dialysis for rural and remote Australian indigenous 
populations [22]. 
 
Do the desirable effects outweigh the undesirable health effects?  
Deciding whether the desirable effects outweigh the undesirable health effects depends on 
the assessments for the three previous criteria relating to the size and importance of effects, 
the certainty of the evidence for those effects and certainty and variability in valuation of 
outcomes for different populations. When relevant population subgroups need to be 
considered in guidelines, this may require making this assessment separately for each 
population subgroup of interest.    
For instance, the current American College of Cardiology blood cholesterol guidelines use a 
cardiovascular disease risk calculation that includes race and gender as considerations for 
estimating the desirable effects from treatment, because the balance of desirable and 
undesirable health effects varies due to differences in baseline event rates across ethnicity 
and gender [23].  
 
Resource use  
The EtD includes three criteria related to resource use: 1) size of resource requirements, 2) 
certainty of evidence about resource requirements and 3) whether the cost effectiveness of 
the intervention favours the intervention or the comparator? Judgments may consider other 
criteria including the certainty of evidence of desirable and undesirable effects, variability in 
valuation of outcomes and uncertainty about the costs [2].  
When considering health equity in assessing resource use (costs), an intervention with lower 
resource requirements and lower effectiveness, compared to the next best alternative may 
sometimes be preferred in some settings to promote health equity.  NICE, in the UK, 
formulated recommendations about options with lower effectiveness and lower resource 
requirements in situations where either there is uncertainty in how much less effective the 
intervention is, or there is a need to provide access to the intervention for disadvantaged 
groups [24].  In South Africa, for instance, in order to treat more people with end-stage 
kidney disease, dialysis guidelines recommend the re-use of dialyzers, albeit with close 
monitoring to ensure effective removal of waste products [25]. These guidelines also 
recommend that patients should be informed before starting dialysis, that re-use is being 
practiced. For considerations of costs and budget impact in this example, the resource use 
needs to consider resources required for monitoring [26].    
Occasionally, if other criteria for strong recommendations are met, but the absolute 
treatment cost is high, this may be a reason to make a conditional recommendation. 
When considering cost-effectiveness studies, there is a need to assess the certainty in the 
model parameters by conducting sensitivity analyses, applicability to the settings of interest 
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and quality of the study. Also, while studies such as cost-effectiveness analyses provide 
useful information to inform decision-makers, these methods do not typically address the 
issues of budget impact or patient-level affordability which may be important, depending on 
the perspective of the recommendation.  
Guideline development panels might identify economic evaluations which have explicitly 
considered health equity in one of four ways: 1) background reviews; 2) health equity impact 
assessment; 3) analyzing opportunity costs for equity considerations; and 4) equity 
weighting of health outcomes [27].  Equity weighting methods include: adding an equity 
weight or social welfare function (SWF) whereby society is prepared to sacrifice overall 
health benefits to promote a more equitable distribution of these benefits; statistical 
programming that quantifies the opportunity cost of equity; and multi-criteria decision 
analysis based on trade-offs between a range of criteria of which, cost may be one, i.e. 
through the process of discrete choice analysis [28]. Economic evaluations which have 
explicitly considered health equity may be helpful when rating equity-sensitive questions. 
 
What would be the impact on health equity? 
The GRADE EtD framework original guidance [2] upon which this paper builds, recommends 
considering four questions to assess potential impact on health equity (Figure 1). 
The criterion of potential impact on health equity focuses on both relative and absolute 
effectiveness for the intervention, the importance of the problem, and identifying 
considerations to ensure health inequities are reduced or not increased [2]. However, data 
on specific disadvantaged groups and settings may not be available.  In such cases, 
considering health equity across the previous criteria may help in answering the above 
questions.  For example, judgments on new testing and treatment guidelines for hepatitis C 
may also benefit from health equity considerations within balance of desirable and 
undesirable effects, cost requirements, acceptability, and feasibility criteria [29].  
By explicitly examining the potential impact on health equity, a panel may discover 
differential effects on disadvantaged populations (e.g. health equity in relation to specific 
characteristics: economic status, employment or occupation, education, place of residence, 
gender or ethnicity) [2].  These four questions may also be considered at other points during 
the evidence to decision process.  For example, the question about differential effects may 
be considered in assessing the size of desirable and undesirable effects for disadvantaged 
populations, as described in the second paper of this series [8]. For example, the WHO 
Reproductive Health Group judged that guidelines recommending only a loop electrosurgical 
excision procedure (LEEP) for invasive cervical cancer might increase health inequities in 
settings without LEEP technology.  Therefore, to prevent a negative effects on health equity, 
WHO suggested cryotherapy and LEEP where available [30].  Careful monitoring of effects 
should be a priority when more accessible options are considered.  
An organization or panel might decide in advance to make explicit detailed judgments for 
one or more criteria (Figure 1). Alternatively, they may only make explicit detailed judgments 
when these judgments help resolve disagreements.  
Figure 1: Detailed judgments about the impact on health equity 
Technical teams and panels may choose to consider or discuss their judgments for each of the 
questions above, together with the available evidence to inform those judgments and additional 
considerations: 
• Are there groups or settings that might be disadvantaged in relation to the problem or 
intervention (option) of interest? 
• Are there plausible reasons for anticipating differences in the relative effectiveness of 
the intervention (option) for disadvantaged groups or settings? 
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• Are there different baseline conditions across groups or settings that affect the absolute 
effectiveness of the intervention (option) or the importance of the problem for 
disadvantaged groups or settings?  
• Are there important considerations that people implementing the intervention (option) 
should consider in order to ensure that inequities are reduced, if possible, and that they 
are not increased? 
  
  
Is the intervention acceptable to key stakeholders, including patients? 
The less acceptable an intervention is to key stakeholders (including disadvantaged people), 
the less likely it is that it should be recommended, or if it is recommended, the more likely it 
is that an implementation strategy will be needed to address concerns about acceptability 
[2]. Acceptability of an intervention may differ for different populations due to four main 
reasons: 1) different distribution of benefits, harms and costs, 2) timing of outcomes (e.g. 
now or in the future), 3) different values about the relative importance of desirable and 
undesirable health effects, and 4) ethical considerations, such as patient autonomy and 
justice.  
 
It is extremely important to collect input from key stakeholders from disadvantaged 
populations in considering acceptability since assumptions by panel members may be 
biased by their personal experience.  Some examples of methods to collect information 
about acceptability include surveys of stakeholders (e.g. WHO guideline on men who have 
sex with men [31] or targeted literature reviews to collect information about acceptability, 
such as done in the Canadian Migrant Health Guidelines [10]). 
 
Differences in acceptability between groups, if strong enough, could impact the strength of a 
recommendation for specific groups and should be reported and addressed during 
implementation. Key stakeholders of disadvantaged populations may include communities, 
health workers and interest groups [2]. For example, in the adaptation of the Canadian 
Reducing Pain with Vaccination Guidelines, the WHO SAGE panel conducted a survey of 
national immunization program leaders in low and middle income countries.  This 
stakeholder survey found that one of the evidence based recommendations [32], using two 
practitioners to give simultaneous vaccines, could create health inequities in overcrowded 
and under-resourced clinics. The recommendation was therefore removed to reduce the risk 
of health inequities and improve uptake of the more acceptable recommendations.  
Certain stakeholders may disapprove of the intervention culturally or traditionally, religiously 
or morally.  For example, a panel developing public health recommendations for preventing 
sexually transmitted infections, including HIV, conducted a survey of men who have sex with 
men, with and without HIV, and transgender people [31]. The results of this work showed 
that marginalized and transgender people preferred community-based HIV testing over 
health facility testing.  This variation in acceptability demanded additional implementation 
resources for community-based testing to prevent inequities.  
 
Is the intervention feasible to implement?  
Feasibility is an assessment of how easy it is to carry out the intervention, put it into practice 
or policy, or stop an existing intervention. The less feasible an intervention, the less likely it 
should be recommended when considering the perspective of the health practitioner. 
Interventions with low feasibility (or high barriers to implementation) may lead to a weak or 
conditional recommendation [2]. 
 
Indeed, decision makers often cite feasibility and cost as critical barriers to implementation 
and may also consider sustainability of the intervention [2]. Panels may identify unique 
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health equity concerns relating to access, barriers to implementation in certain settings, and 
program feasibility. Detailed judgments may include consideration of barriers to the 
sustainability of the option(s) [33]. These barriers include guideline factors, individual health 
professional factors, patient factors, professional interactions, incentives and resources, 
capacity for organizational change, and social, legal and political factors [34].   
 
Low feasibility may leave panels hesitant to exclusively recommend an intervention that is 
effective and even cost-effective, but may be too resource intensive for a particular setting 
(e.g. low income country). For example, the WHO recommends that visual inspection of the 
cervix with acetic acid in resource limited settings be considered for cervical cancer 
screening as an alternative for the more expensive and technically challenging Papanicolaou 
tests [30].  
 
3. Drawing conclusions  
Drawing conclusions begins with the panel reviewing the judgments they have made for all 
of the criteria in their assessment and considering the implications of those judgments for the 
recommendation or decision. The importance of each EtD criterion for a recommendation 
can vary depending on the population and limitations in resources. To formulate a 
recommendation a panel must consider the trade-offs and health equity concerns of each 
judgment. Based on their assessment, the panel draws conclusions about the strength of 
recommendation or type of decision, such as a strong or weak (also called conditional, 
discretionary, or qualified) recommendation for or against an intervention or option. The 
conclusions also include relevant considerations about subgroups, implementation, 
monitoring and evaluation, and research priorities (see Table 2). Panels can reach these 
conclusions in different ways, including the use of informal or formal consensus processes or 
voting. 
 
We propose that assessing health equity across EtD criteria will help to decide amongst 
three possible types of recommendations: 
 
1) A general recommendation that can be applied across different populations and 
settings. Assessment of health equity across the criteria may increase the confidence 
of the panel that a general recommendation is warranted and that the intervention is 
applicable for disadvantaged populations and settings. 
 
2)  A general recommendation that can be accompanied with subgroup and 
implementation considerations, to promote health equity or mitigate worsening health 
inequities.   
 
3)  A separate recommendation for a specific disadvantaged population when evidence 
of meaningfully different effects for a specific setting or subgroup is identified.     
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Table 2 Evidence to Decision frameworks: Conclusions 
Type of recommendation 
 
Strong 
recommendation 
against the 
option 
Conditional 
recommendation 
against the 
option 
Conditional 
recommendation 
for either the 
option or the 
comparison 
Conditional 
recommendation 
for the option 
Strong 
recommendation 
for the option 
x ○ ○ ○ ○ 
 
Recommendation In the general population, the guideline panel recommends not screening for 
HCV 
Justification Very low quality evidence that desirable effects favor the intervention? 
Subgroup considerations Consider testing high prevalence Hepatitis C populations, given the 
emerging promising treatment modalities  
Implementation 
considerations 
Implementation considerations added to suggest considering testing high 
risk populations  
Monitoring and evaluation Monitoring needed to assess screening rates across populations 
Research priorities Need for research on patient important outcomes bridging testing and 
linkage to care and treatment 
Drawn from Canadian Task Force on Preventive Health Care Screening for Hepatitis C. [14]. 
 
Methodologic Challenges 
One challenge in assessing potential impact on health equity across EtD criteria is that 
within a specific disadvantaged population, such as people living on low-income, there is 
heterogeneity in the experience of health inequity due to variation across other social 
determinants such as gender, employment and age.  Thus, the assessment for one 
population may vary depending on the intersection of these different characteristics.  
Guideline panels may need to choose the most important disadvantaged populations for the 
problem or condition of interest, and recognize that there is no “one-size-fits-all” approach to 
mitigating health inequities. 
The second challenge is that the EtD process requires a step-wise approach.  We recognize 
that it may not be possible or desirable to assess equity for every criterion.  For example, if 
an intervention is simply not acceptable for a disadvantaged population, then it is redundant 
to also assess feasibility and resource use considerations for this population. The acuity to 
assess and address the needs of disadvantaged groups may require additional research 
training and systematic processes.  Assessing health equity across each criterion adds 
another level of complexity and may only be warranted for selected criteria and scenarios.  
 
Research Agenda 
Researchers could monitor the use of EtD frameworks to see if health equity impacts or 
considerations are being reported.  When, if ever, do health equity concerns influence the 
direction or strength of recommendations? Researchers will need to ask: which criteria most 
commonly report gaps in health equity consideration reporting? Does assessing health 
equity across EtD criteria improve the impact of the guideline. What are the health equity 
methodological and data barriers facing guideline panels and review groups? Finally, how do 
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panel members and stakeholders respond to health equity and implementation 
considerations or options?  Comparison of different approaches to considering health equity 
in guideline development could advance the equity related methods. 
In conclusion, health decisions should incorporate health equity considerations. The EtD 
frameworks can facilitate explicit and systematic judgement of potential effects on health 
equity. When relevant for disadvantaged populations, panel members should consider 
providing the corresponding specific subgroup information (and make independent 
judgments as well as the overall population judgments) within the specific criteria. Preventing 
harms, including unintended harms, may be especially important for disadvantaged 
populations who often have a higher risk of disease and fewer resources to address harms.  
Panels should judge and report the estimated impact of interventions or options on health 
equity and modify recommendations, or develop specific implementation strategies to 
prevent harms or reduce health inequities.  
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